Fujirebio mesothelioma blood test:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale under its Humanitarian Device Exemption (HDE) programme what is claimed to be the first in vitro test for monitoring patients confirmed as having mesothelioma, a form of cancer linked to asbestos exposure. The Mesomark test, made by Fujirebio Diagnostics, enables doctors to more accurately detect disease recurrence and monitor treatment of patients, via a simple blood test, said the company, a subsidiary of Japan's Fujirebio. The company plans to collect more data to support the test's use for detecting mesothelioma. HDE approvals are intended to allow companies to show safety and probable benefit for products designed to treat a defined group of patients - fewer than 4,000 individuals in the US per year.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.